查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918113

肝素市场－2026-2031年预测

Heparin Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 153 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计肝素市场将以 5.0% 的复合年增长率成长，从 2025 年的 65.98 亿美元成长到 2031 年的 88.4 亿美元。

由于肝素在预防和治疗血栓性疾病方面发挥着至关重要的抗凝血作用，因此肝素市场是製药业的重要组成部分。肝素的主要功能是抑制血液凝固，使其在外科手术、心血管疾病治疗和肾臟透析中不可或缺。市场成长轨迹受到人口趋势、特定疾病的流行以及该药物广泛的治疗效用等多种因素的影响，但同时也受到重大安全隐患的限制。

市场扩张的主要驱动因素是全球心血管疾病负担日益恶化。强效抗凝血​​治疗对于预防中风和其他血栓栓塞併发症至关重要，例如心房颤动和心肌梗塞后併发症病例的不断增加。这些疾病发生率的上升与对抗凝剂需求的增长直接相关，而肝素仍然是治疗的基石，尤其是在急性期和手术全期。

全球人口老化趋势也在推动市场需求。老年人特别容易患心血管疾病，并且更频繁地接受外科手术，例如整形外科和心血管手术，而肝素在这些手术中通常用于血栓预防。这种人口趋势导致需要抗凝血治疗的患者群体持续增长，从而确保了肝素使用的稳定基础。

肝素在各种临床场景中的广泛应用极大地支持了其市场地位。它在多个领域已被广泛应用：例如，作为手术（如心臟直视手术和搭桥手术）后的预防和治疗药物，作为肾透析迴路中的抗凝血剂，以及用于治疗瀰漫性血管内凝血等严重疾病。这种临床上的多功能性，以及包括低分子量肝素（如依诺肝素）在内的多种製剂形式，确保了其在医院医学、外科和肾臟病学领域持续发挥重要作用。

儘管市场需求强劲，但肝素市场仍面临许多限制因素，主要与药物安全性相关。肝素治疗有严重副作用的风险，尤其是肝素诱发的血小板减少性疾病（HIT），这种疾病反而可能导致危及生命的血栓症。此外，肝素本身有出血风险，因此需要由经验丰富的医护人员进行严格的剂量管理和监测。这些安全隐患，加上严格的监管制度，可能会限制肝素的普及，尤其是在医疗资源和专业知识有限的医疗系统中，从而限制市场成长。

从区域来看，北美预计将成为领先的市场。这一优势归功于该地区心血管疾病的高发病率、能够管理复杂抗凝血疗法的先进医疗基础设施，以及支持基本药物普及的高额医疗支出。庞大的老年人口和健全的临床研究与创新体系进一步巩固了该地区在全球肝素市场的主导地位。

竞争格局包括赛诺菲、利奥製药和阿斯彭控股等成熟的跨国製药公司。这些公司提供种类繁多的肝素类产品，包括品牌低分子量肝素和原料药。在面临安全管理挑战和临床指南不断更新的市场环境下，它们持续占有一席之地，凸显了肝素作为医疗保健关键工具的重要性。因此，市场稳定性源自于肝素在满足基本和日益增长的临床需求方面不可替代的作用。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略打入市场的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 全球肝素市场（依产品类型划分）

  • 介绍
  • 低分子量肝素
  • 未分级肝素

6. 全球肝素市场依给药途径划分

  • 介绍
  • 静脉输液
  • 皮下注射

7. 全球肝素市场依应用领域划分

  • 介绍
  • 心房颤动
  • 静脉血栓症
  • 输血
  • 其他的

8. 全球肝素市场（依最终用户划分）

  • 介绍
  • 医院
  • 门诊手术中心
  • 其他的

9. 全球肝素市场（依地区划分）

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十一章 公司简介

  • Pfizer, Inc.
  • LEO Pharma A/S
  • Sanofi
  • Dr. Reddy's Laboratories Ltd.
  • B. Braun Medical Inc.
  • Fresenius SE & Co. KGaA
  • Sandoz Group AZ
  • Shenzhen Hepalink Pharmaceutical
  • Teva Pharmaceutical Industries Ltd.
  • Amphastar Pharmaceuticals Inc.
  • Opocrin SpA

第十二章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615585

The heparin market, with a 5.0% CAGR, is projected to increase from USD 6.598 billion in 2025 to USD 8.84 billion in 2031.

The heparin market is a critical segment within the pharmaceutical industry, driven by the essential role of this anticoagulant in preventing and treating thrombotic conditions. Heparin's primary function is to inhibit blood clotting, making it indispensable in surgical procedures, the management of cardiovascular diseases, and renal dialysis. The market's growth trajectory is shaped by a combination of demographic trends, the prevalence of specific disease states, and the drug's broad therapeutic utility, though it is moderated by significant safety considerations.

A principal driver of market expansion is the escalating global burden of cardiovascular diseases. Conditions such as atrial fibrillation and the high volume of post-myocardial infarction cases necessitate robust anticoagulation therapy to prevent stroke and other thromboembolic complications. The increasing incidence of these disorders directly correlates with a rising demand for anticoagulant medications, with heparin remaining a cornerstone therapy, particularly in acute and perioperative settings.

The demographic shift towards an aging global population further amplifies market demand. Older adults are disproportionately affected by cardiovascular conditions and are more frequently candidates for surgical interventions, including orthopedic and cardiovascular surgeries, where heparin is routinely used for thromboprophylaxis. This demographic trend ensures a growing and sustained patient population requiring anticoagulation management, thereby securing a stable foundation for heparin utilization.

Heparin's extensive application portfolio across various clinical scenarios significantly contributes to its market presence. Its use is well-established in multiple domains: as a prophylactic and therapeutic agent post-surgery (e.g., open-heart and bypass surgery), in renal dialysis circuits to prevent clotting, and in the treatment of serious conditions like disseminated intravascular coagulation. This clinical versatility, supported by various formulations such as low molecular weight heparins (e.g., enoxaparin), ensures its continued relevance across hospital medicine, surgery, and nephrology.

Despite strong demand drivers, the market faces notable restraints primarily related to drug safety. Heparin therapy carries the risk of serious adverse effects, most notably heparin-induced thrombocytopenia (HIT), a condition that can paradoxically lead to life-threatening thrombosis. Furthermore, the inherent risk of major bleeding requires careful dose management and monitoring by skilled healthcare professionals. These safety concerns, coupled with stringent regulatory oversight governing its use, can limit its application, particularly in healthcare systems with limited resources or expertise, thereby acting as a moderating factor on market growth.

Geographically, North America is anticipated to be a significant marketplace. This prominence is attributed to the region's high prevalence of cardiovascular diseases, a technologically advanced healthcare infrastructure capable of managing complex anticoagulation regimens, and substantial healthcare expenditure that supports the adoption of essential medicines. The presence of a large aging population and a robust framework for clinical research and innovation further consolidates the region's leading position in the global heparin market.

The competitive landscape includes established multinational pharmaceutical companies such as Sanofi, LEO Pharma, and Aspen Holdings. These players offer a range of heparin-based products, including branded low molecular weight heparins and active pharmaceutical ingredients. Their sustained presence underscores the continued importance of heparin as a critical tool in the medical arsenal, even as the market navigates the challenges of safety management and evolving clinical guidelines. The market's stability is thus derived from its irreplaceable role in addressing fundamental and growing clinical needs.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Heparin Market Segmentation:

  • By Product Type
  • Low-Molecular Weight Heparin
  • Unfractionated Heparin
  • By Route of Administration
  • Intravenous Infusion
  • Subcutaneous Injection
  • By Application
  • Atrial Fibrillation
  • Venous Thrombosis
  • Blood Transfusion
  • Others
  • By End-User
  • Hospitals
  • Ambulatory Surgical Centers
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL HEPARIN MARKET BY PRODUCT TYPE

  • 5.1. Introduction
  • 5.2. Low-Molecular Weight Heparin
  • 5.3. Unfractioned Heparin

6. GLOBAL HEPARIN MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Intravenous Infusion
  • 6.3. Subcutaneous Injection

7. GLOBAL HEPARIN MARKET BY APPLICATION

  • 7.1. Introduction
  • 7.2. Atrial Fibrillation
  • 7.3. Venous Thrombosis
  • 7.4. Blood Transfusion
  • 7.5. Others

8. GLOBAL HEPARIN MARKET BY END-USER

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Ambulatory Surgical Centers
  • 8.4. Others

9. GLOBAL HEPARIN MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. USA
    • 9.2.2. Canada
    • 9.2.3. Mexico
  • 9.3. South America
    • 9.3.1. Brazil
    • 9.3.2. Argentina
    • 9.3.3. Others
  • 9.4. Europe
    • 9.4.1. Germany
    • 9.4.2. France
    • 9.4.3. United Kingdom
    • 9.4.4. Spain
    • 9.4.5. Italy
    • 9.4.6. Others
  • 9.5. Middle East and Africa
    • 9.5.1. Saudi Arabia
    • 9.5.2. UAE
    • 9.5.3. Israel
    • 9.5.4. Others
  • 9.6. Asia Pacific
    • 9.6.1. China
    • 9.6.2. India
    • 9.6.3. Japan
    • 9.6.4. South Korea
    • 9.6.5. Indonesia
    • 9.6.6. Thailand
    • 9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Pfizer, Inc.
  • 11.2. LEO Pharma A/S
  • 11.3. Sanofi
  • 11.4. Dr. Reddy's Laboratories Ltd.
  • 11.5. B. Braun Medical Inc.
  • 11.6. Fresenius SE & Co. KGaA
  • 11.7. Sandoz Group AZ
  • 11.8. Shenzhen Hepalink Pharmaceutical
  • 11.9. Teva Pharmaceutical Industries Ltd.
  • 11.10. Amphastar Pharmaceuticals Inc.
  • 11.11. Opocrin S.p.A

12. APPENDIX

  • 12.1. Currency
  • 12.2. Assumptions
  • 12.3. Base and Forecast Years Timeline
  • 12.4. Key Benefits for the Stakeholders
  • 12.5. Research Methodology
  • 12.6. Abbreviations